Insights Into Diffuse Large B-Cell Lymphoma (DLBCL)
Perspectives on drivers in treatment decisions in the management of DLBCL, perception of various therapeutics, and understanding of the current and future treatment landscape
Faculty Chair
Elizabeth Brém, MD
UCI Health, Orange County, CA, USA
Faculty Chair
Jonathon Cohen, MD
Winship Cancer Institute, Atlanta, GA, USA
Faculty Chair
Gilles Salles, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Faculty Chair
Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA
Faculty Chair
Sushil Bhardwaj, MD
Good Samaritan Hospital, Suffern, NY, USA
Faculty Chair
Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Philadelphia, PA
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Portland, OR
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
More Information
- Virtual series
- National
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of DLBCL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, polatuzumab vedotin
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
